XCUR

Exicure, Inc.

XCUR 4 | $0.515 19K

(0.0% 1d) (-16.6% 1m) (-43.4% 1y) (0.0% 2d) (-3.7% 3d) (-7.1% 7d) (164.05% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 4,453,878
http://www.exicuretx.com
Sec Filling | Patents | 63 employees

(US) Exicure, Inc. is a clinical-stage biotechnology company, which engages in the discovery, research, and development of treatments based on spherical nucleic acid technology (SNA). It focuses on neurology, immuno-oncology, inflammatory diseases, and other genetic disorders. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.

genetic neurological treatment

add to watch list Paper trade email alert is off

Press-releases

Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
Published: 2024-02-05 (Crawled : 23:00) - biospace.com/
XCUR 4 | $0.515 19K

Commercial Services

| -4.41% | O: 1.1% H: 1.82% C: 1.76%
hepatitis patent license treatment therapeutics agreement

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-08-11 (Crawled : 22:00) - biospace.com/
XCUR 4 | $0.515 19K

Commercial Services

| -39.46% | O: -4.49% H: 3.9% C: 3.9%
update financial results

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-07-14 (Crawled : 23:00) - biospace.com/
XCUR 4 | $0.515 19K

Commercial Services

| -58.73% | O: 11.11% H: 2.86% C: -2.86%
update financial results

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors
Published: 2023-04-27 (Crawled : 12:00) - biospace.com/
XCUR 4 | $0.515 19K

Commercial Services

| -43.36% | O: -1.83% H: 3.33% C: -0.13%
ceo

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements Exicure, Inc. an early-stage biotechnology company historically focused on developing nucleic acid therapies targeting r...
Published: 2022-12-14 (Crawled : 12:00) - biospace.com/
LLY | News | $732.2 -1.81% -0.71% 8K

Health Technology

| 109.73% | O: 0.1% H: 2.9% C: 1.25%
XCUR 4 | $0.515 19K

Commercial Services

| -29.17% | O: 0.0% H: 11.14% C: 0.79%
collaboration

Exicure, Inc. Announces Termination of AbbVie and Ipsen Collaboration Agreements
Published: 2022-12-14 (Crawled : 11:00) - biospace.com/
XCUR 4 | $0.515 19K

Commercial Services

| -29.17% | O: 0.0% H: 11.14% C: 0.79%
collaboration

NeuBase Abandons Huntington's, 60% of Workforce in Strategic Pivot
Published: 2022-10-17 (Crawled : 13:20) - biospace.com/
XCUR 4 | $0.515 19K

Commercial Services

| -66.45% | O: -1.93% H: 1.97% C: 0.65%

NeuBase Drops Huntington's Program, Slashes 60% of Workforce
Published: 2022-10-17 (Crawled : 12:20) - biospace.com/
XCUR 4 | $0.515 19K

Commercial Services

| -66.45% | O: -1.93% H: 1.97% C: 0.65%

Exicure Lays off Two-Thirds of Workforce, Suspends R&D in Restructuring
Published: 2022-09-27 (Crawled : 19:00) - biospace.com/
XCUR 4 | $0.515 19K

Commercial Services

| -69.41% | O: -2.94% H: 0.61% C: -14.55%

Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives
Published: 2022-09-26 (Crawled : 22:00) - biospace.com/
XCUR 4 | $0.515 19K

Commercial Services

| -66.23% | O: 2.26% H: 9.22% C: 7.95%
agreement

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001698530-24-000010	4	2024-03-06	2024-02-16	Sell	F	46	1827
0001698530-23-000126	4	2023-12-01	2023-11-16	Sell	F	38	1873
0001698530-23-000093	4	2023-08-18	2023-08-16	Sell	F	37	1911